Novartis negotiates ex-US rights to Spark gene therapy – PMLiVE
PMLiVE |
Novartis negotiates ex-US rights to Spark gene therapy
PMLiVE Novartis has agreed to develop Spark Therapeutics' recently-approved gene therapy Luxturna outside the US, in a deal valued at $170m. The Swiss pharma group is paying $105m for ex-US rights to Luxturna (voretigene neparvovec-rzyl), which is currently … |
